Alternative options for DNA-based experimental therapy of β-thalassemia

Bibliography

• Patrinos GP, Kollia P, Papadakis MN. Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum Mutat 2005;26:399-412
   PubMed Web of Science ®Google Scholar
• Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003;17:43-53
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11
   PubMed Web of Science ®Google Scholar
• Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev Hematol 2010;3:103-17
   PubMed Web of Science ®Google Scholar
• Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol 2007;136:353-65
   PubMed Web of Science ®Google Scholar
• Lederer CW, Basak AN, Aydinok Y, An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project. Hemoglobin 2009;33:163-76
   PubMed Web of Science ®Google Scholar
• Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr Med Chem 2007;14:199-212
   PubMed Web of Science ®Google Scholar
• Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 2009;88:505-28
   PubMed Web of Science ®Google Scholar
• Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 2010;18:1077-83
   PubMed Web of Science ®Google Scholar
• Mantikou E, Arkesteijn SG, Beckhoven van JM, Kerkhoffs JL. A brief review on newborn screening methods for hemoglobinopathies and preliminary results selecting beta thalassemia carriers at birth by quantitative estimation of the HbA fraction. Clin Biochem 2009;42:1780-5
   PubMed Web of Science ®Google Scholar
• Cao A, Galanello R. Beta-thalassemia. Genet Med 2010;12:61-76
   PubMed Web of Science ®Google Scholar
• Cao A, Moi P, Galanello R. Recent advances in beta-thalassemias. Pediatr Rep 2011;3:e17
   PubMedGoogle Scholar
• Gambari R. Foetal haemoglobin inducers and thalassaemia: novel achievements. Blood Transfus 2010;8:5-7
   PubMed Web of Science ®Google Scholar
• Cunningham MJ. Update on thalassemia: clinical care and complications. Hematol Oncol Clin North Am 2010;24:215-27
   PubMed Web of Science ®Google Scholar
• Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassaemia Major. Pediatr Endocrinol Rev 2007;5:642-8
   PubMedGoogle Scholar
• Tuck SM. Fertility and pregnancy in thalassemia major. Ann N Y Acad Sci 2005;1054:300-7
   PubMed Web of Science ®Google Scholar
• Skordis N, Kyriakou A. The multifactorial origin of growth failure in thalassaemia. Pediatr Endocrinol Rev 2011;8(Suppl 2):271-7
   PubMedGoogle Scholar
• De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res 2002;58(Suppl 1):72-9
   PubMedGoogle Scholar
• Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol 2011;4:353-66
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Gamberini MR, Borgatti L, Alpha and beta cell evaluation in patients with thalassaemia intermedia and iron overload. Postgrad Med J 1985;61:963-7
   PubMed Web of Science ®Google Scholar
• Di Marco V, Bronte F, Cabibi D, Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) – lack of interference by iron deposition. Br J Haematol 2010;148:476-9
   PubMed Web of Science ®Google Scholar
• NIH-NHLBI/NIDDK Thalassemia Workshop: clinical Priorities and Clinical Trials, Fishers Lane Conference Center, 5635 Fishers Lane, Rockville, Maryland, May 20 – 21, 2009. Available from: http://www.nhlbi.nih.gov/meetings/workshops/thal_workshop.htm [Last accessed 13 February 2012]
   Google Scholar
• Bianchi N, Zuccato C, Lampronti I, Fetal hemoglobin inducers from the natural world; a novel approach for identification of drugs for the treatment of beta-thalassemia and sickle-cell anemia. Evid Based Complement Altern Med 2009;6:141-51
   PubMed Web of Science ®Google Scholar
• Feriotto G, Salvatori F, Finotti A, A novel frameshift mutation (+A) at codon 18 of the beta-globin gene associated with high persistence of fetal hemoglobin phenotype and deltabeta-thalassemia. Acta Haematol 2008;119:28-37
   PubMed Web of Science ®Google Scholar
• Zhao H, Pestina TI, Nasimuzzaman M, Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 2009;113:5747-56
   PubMed Web of Science ®Google Scholar
• Bianchi N, Borgatti M, Fibach E, Bis-epoxyethyl derivatives of distamycin A modified on the amidino moiety: induction of production of fetal hemoglobin in human erythroid precursor cells. Int J Mol Med 2009;23:105-11
   PubMed Web of Science ®Google Scholar
• Guerrini A, Lampronti I, Bianchi N, Bergamot (Citrus bergamia Risso) fruit extracts as gamma-globin gene expression inducers: phytochemical and functional perspectives. J Agric Food Chem 2009;57:4103-11
   PubMed Web of Science ®Google Scholar
• Lampronti I, Bianchi N, Zuccato C, Increase in gamma-globin mRNA content in human erythroid cells treated with angelicin analogs. Int J Hematol 2009;90:318-27
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Verhelle D, Glezer E, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008;118:248-58
   PubMed Web of Science ®Google Scholar
• Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood 2011;117:5987-97
   PubMed Web of Science ®Google Scholar
• Boosalis MS, Castaneda SA, Trudel M, Novel therapeutic candidates, identified by molecular modeling, induce gamma-globin gene expression in vivo. Blood Cells Mol Dis 2011;47:107-16
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijina FJ, Merchant R, Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta 2009;407:10-15
   PubMed Web of Science ®Google Scholar
• Ehsani MA, Hedayati-Asl AA, Bagheri A, Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol 2009;26:560-5
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Saunthararajah Y, Thayalasuthan V, A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood 2011;118:2708-11
   PubMed Web of Science ®Google Scholar
• Masera N, Tavecchia L, Capra M, Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus 2010;8:63-5
   PubMed Web of Science ®Google Scholar
• Aguilar-Lopez LB, Delgado Lamas JL, Rubio-Jurado B, Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis 2008;41:136-7
   PubMed Web of Science ®Google Scholar
• Perrine SP, Castaneda SA, Chui DH, Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci 2010;1202:158-64
   PubMed Web of Science ®Google Scholar
• Perrine SP, Wargin WA, Boosalis MS, Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase I, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol 2011;51:1186-94
   PubMed Web of Science ®Google Scholar
• Metallo CM, Azarin SM, Ji L, Engineering tissue from human embryonic stem cells. J Cell Mol Med 2008;12:709-29
   PubMed Web of Science ®Google Scholar
• Li B, Xu L, Lu WY, A whole-mechanical method to establish human embryonic stem cell line HN4 from discarded embryos. Cytotechnology 2010;62:509-18
   PubMed Web of Science ®Google Scholar
• Si-Tayeb K, Noto FK, Sepac A, Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol 2010;10:81-91
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76
   PubMed Web of Science ®Google Scholar
• Ye L, Chang JC, Lin C, Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci USA 2009;106:9826-30
   PubMed Web of Science ®Google Scholar
• Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-34
   PubMed Web of Science ®Google Scholar
• Rutherford TR, Clegg JB, Weatherall DJ. K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature 1976;280:164-5
   Google Scholar
• Fibach E, Bianchi N, Borgatti M, Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol 2006;77:437-41
   PubMed Web of Science ®Google Scholar
• Pope SH, Fibach E, Sun J, Two-phase liquid culture system models normal human adult erythropoiesis at the molecular level. Eur J Haematol 2000;64:292-303
   PubMed Web of Science ®Google Scholar
• Fibach E, Bianchi N, Borgatti M, Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 2003;102:1276-81
   PubMed Web of Science ®Google Scholar
• Vadolas J, Nefedov M, Wardan H, Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation. J Biol Chem 2006;281:7399-405
   PubMed Web of Science ®Google Scholar
• Johnson RM, Gumucio D, Goodman M. Globin gene switching in primates. Comp Biochem Physiol A Mol Integr Physiol 2002;133:877-83
   PubMed Web of Science ®Google Scholar
• Rivella S, May C, Chadburn A, A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003;101:2932-9
   PubMed Web of Science ®Google Scholar
• Weizer-Stern O, Adamsky K, Amariglio N, mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Am J Hematol 2006;81:479-83
   PubMed Web of Science ®Google Scholar
• Jamsai D, Zaibak F, Vadolas J, A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. Genomics 2006;88:309-15
   PubMed Web of Science ®Google Scholar
• Li W, Xie S, Guo X, A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy. Haematologica 2008;93:356-62
   PubMed Web of Science ®Google Scholar
• Huo Y, McConnell SC, Ryan TM. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major. Blood 2009;113:4763-70
   PubMed Web of Science ®Google Scholar
• Huo Y, McConnell SC, Liu S, Humanized mouse models of Cooley's anemia: correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology. Ann N Y Acad Sci 2010;1202:45-51
   PubMed Web of Science ®Google Scholar
• Bank A. On the road to gene therapy for beta-thalassemia and sickle cell anemia. Pediatr Hematol Oncol 2008;25:1-4
   PubMed Web of Science ®Google Scholar
• Lisowski L, Sadelain M. Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol 2008;141:335-45
   PubMed Web of Science ®Google Scholar
• Breda L, Gambari R, Rivella S. Gene therapy in thalassemia and hemoglobinopathies. Mediterr J Hematol Infect Dis 2009;1:e2009008
   PubMedGoogle Scholar
• Persons DA. Gene therapy: targeting beta-thalassaemia. Nature 2010;467:277-8
   PubMed Web of Science ®Google Scholar
• Bank A. Hemoglobin gene therapy for beta-thalassemia. Hematol Oncol Clin North Am 2010;24:1187-201
   PubMed Web of Science ®Google Scholar
• Boulad F, Riviere I, Sadelain M. Gene therapy for homozygous beta-thalassemia. Is it a reality? Hemoglobin 2009;33:S188-96
   PubMed Web of Science ®Google Scholar
• Yannaki E, Emery DW, Stamatoyannopoulos G. Gene therapy for beta-thalassaemia: the continuing challenge. Expert Rev Mol Med 2010;12:e31
   PubMed Web of Science ®Google Scholar
• Maina N, Zhong L, Li X, Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression. Hum Gene Ther 2008;19:365-75
   PubMed Web of Science ®Google Scholar
• Gelinas R, Novak U. Retroviral vectors for the beta-globin gene that demonstrate improved titer and expression. Ann N Y Acad Sci 1990;612:427-41
   PubMed Web of Science ®Google Scholar
• Dong WJ, Li B, Liu DP, Evaluation of optimal expression cassette in retrovirus vector for beta-thalassemia gene therapy. Mol Biotechnol 2003;24:127-40
   PubMed Web of Science ®Google Scholar
• Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011;11:218-28
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivella S, Lisowski L, Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. Best Pract Res Clin Haematol 2004;17:517-34
   PubMed Web of Science ®Google Scholar
• Case SS, Price MA, Jordan CT, Stable transduction of quiescent CD34+CD38− human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999;96:2988-93
   PubMed Web of Science ®Google Scholar
• Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood 2007;110:4175-8
   PubMed Web of Science ®Google Scholar
• Hargrove PW, Kepes S, Hanawa H, Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 2008;16:525-33
   PubMed Web of Science ®Google Scholar
• Zhou HS, Zhao N, Li L, Site-specific transfer of an intact beta-globin gene cluster through a new targeting vector. Biochem Biophys Res Commun 2007;356:32-7
   PubMed Web of Science ®Google Scholar
• Zhao S, Weinreich MA, Ihara K, In vivo selection of genetically modified erythroid cells using a jak2-based cell growth switch. Mol Ther 2004;10:456-68
   PubMed Web of Science ®Google Scholar
• Persons DA. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients. Ann N Y Acad Sci 2010;1202:69-74
   PubMed Web of Science ®Google Scholar
• Yannaki E, Stamatoyannopoulos G. Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease. Ann N Y Acad Sci 2010;1202:59-63
   PubMed Web of Science ®Google Scholar
• Yannaki E, Psatha N, Athanasiou E, Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. Hum Gene Ther 2010;21:299-310
   PubMed Web of Science ®Google Scholar
• Miccio A, Cesari R, Lotti F, In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci USA 2008;105:10547-52
   PubMed Web of Science ®Google Scholar
• Persons DA, Allay ER, Sawai N, Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003;102:506-13
   PubMed Web of Science ®Google Scholar
• Negre O, Fusil F, Colomb C, Correction of murine beta-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. Blood 2011;117:5321-31
   PubMed Web of Science ®Google Scholar
• Kumar P, Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther 2011;11:144-53
   PubMed Web of Science ®Google Scholar
• Wilber A, Hargrove PW, Kim YS, Therapeutic levels of fetal hemoglobin in erythroid progeny of beta-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 2011;117:2817-26
   PubMed Web of Science ®Google Scholar
• May C, Rivella S, Callegari J, Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-6
   PubMed Web of Science ®Google Scholar
• May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002;99:1902-8
   PubMed Web of Science ®Google Scholar
• Puthenveetil G, Scholes J, Carbonell D, Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004;104:3445-53
   PubMed Web of Science ®Google Scholar
• Imren S, Payen E, Westerman KA, Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 2002;99:14380-5
   PubMed Web of Science ®Google Scholar
• Imren S, Fabry ME, Westerman KA, High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest 2004;114:953-62
   PubMed Web of Science ®Google Scholar
• Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol 2001;38:382-92
   PubMed Web of Science ®Google Scholar
• Kafri T. Lentivirus vectors: difficulties and hopes before clinical trials. Curr Opin Mol Ther 2001;3:316-26
   PubMed Web of Science ®Google Scholar
• Breda L, Kleinert DA, Casu C, A preclinical approach for gene therapy of beta-thalassemia. Ann N Y Acad Sci 2010;1202:134-40
   PubMed Web of Science ®Google Scholar
• Bank A, Dorazio R, Leboulch P. A Phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005;1054:308-16
   PubMed Web of Science ®Google Scholar
• Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program 2010;2010:445-50
   PubMed Web of Science ®Google Scholar
• Sadelain M, Riviere I, Wang X, Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci 2010;1202:52-8
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-22
   PubMed Web of Science ®Google Scholar
• Kaiser J. Gene therapy. beta-thalassemia treatment succeeds, with a caveat. Science 2009;326:1468-9
   PubMed Web of Science ®Google Scholar
• Colosimo A, Guida V, Antonucci I, Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells. Haematologica 2007;92:129-30
   PubMed Web of Science ®Google Scholar
• Chin JY, Kuan JY, Lonkar PS, Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. Proc Natl Acad Sci USA 2008;105:13514-19
   PubMed Web of Science ®Google Scholar
• Rogers FA, Lin SS, Hegan DC, Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol Ther 2012;20:109-18
   PubMed Web of Science ®Google Scholar
• Porteus MH. Mammalian gene targeting with designed zinc finger nucleases. Mol Ther 2006;13:438-46
   PubMed Web of Science ®Google Scholar
• Zou J, Mali P, Huang X, Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011;118:4599-608
   PubMed Web of Science ®Google Scholar
• Svasti S, Suwanmanee T, Fucharoen S, RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc Natl Acad Sci USA 2009;106:1205-10
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Mostafa A, Youssry I, Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in beta-thalassemia Egyptian patients with IVSI-110 mutation. J Pediatr Hematol Oncol 2008;30:281-4
   PubMed Web of Science ®Google Scholar
• Suwanmanee T, Sierakowska H, Fucharoen S, Kole R. Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol Ther 2002;6:718-26
   PubMed Web of Science ®Google Scholar
• Zeng Y, Gu X, Chen Y, Reversal of aberrant splicing of beta-thalassemia allele by antisense RNA in vitro and in vivo. Chin Med J (Engl) 1999;112:107-11
   PubMed Web of Science ®Google Scholar
• El-Andaloussi S, Johansson HJ, Lundberg P, Langel U. Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 2006;8:1262-73
   PubMed Web of Science ®Google Scholar
• Papapetrou EP, Lee G, Malani N, Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011;29:73-8
   PubMed Web of Science ®Google Scholar
• Sadelain M, Boulad F, Lisowki L, Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med 2008;8:690-7
   PubMed Web of Science ®Google Scholar
• Abuljadayel IS, Quereshi H, Ahsan T, Infusion of autologous retrodifferentiated stem cells into patients with beta-thalassemia. ScientificWorldJournal 2006;6:1278-97
   PubMed Web of Science ®Google Scholar
• Hanna J, Wernig M, Markoulaki S, Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3
   PubMed Web of Science ®Google Scholar
• Emery DW, Yannaki E, Tubb J, Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002;100:2012-19
   PubMed Web of Science ®Google Scholar
• Hanawa H, Hargrove PW, Kepes S, Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood 2004;104:2281-90
   PubMed Web of Science ®Google Scholar
• Persons DA, Hargrove PW, Allay ER, The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 2003;101:2175-83
   PubMed Web of Science ®Google Scholar
• Hanawa H, Hargrove PW, Kepes S, Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood 2004;104:2281-90
   PubMed Web of Science ®Google Scholar
• Nishino T, Tubb J, Emery DW. Partial correction of murine beta-thalassemia with a gammaretrovirus vector for human gamma-globin. Blood Cells Mol Dis 2006;37:1-7
   PubMed Web of Science ®Google Scholar
• Nishino T, Cao H, Stamatoyannopoulos G, Emery DW. Effects of human gamma-globin in murine beta-thalassaemia. Br J Haematol 2006;134:100-8
   PubMed Web of Science ®Google Scholar
• Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009;145:455-67
   PubMed Web of Science ®Google Scholar
• Forget BG. Progress in understanding the hemoglobin switch. N Engl J Med 2011;365:852-4
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Byron R, A functional element necessary for fetal hemoglobin silencing. N Engl J Med 2011;365:807-14
   PubMed Web of Science ®Google Scholar
• Xu XS, Hong X, Wang G. Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol 2009;2:15-26
   PubMed Web of Science ®Google Scholar
• Jiang J, Best S, Menzel S, cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006;108:1077-83
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Xu J, Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-42
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Orkin SH. Transcriptional silencing of fetal hemoglobin by BCL11A. Ann N Y Acad Sci 2010;1202:64-8
   PubMed Web of Science ®Google Scholar
• Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program 2011;2011:459-65
   PubMed Web of Science ®Google Scholar
• Nguyen TK, Joly P, Bardel C, The XmnIGgamma polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia patients. Blood Cells Mol Dis 2010;45:124-7
   PubMed Web of Science ®Google Scholar
• Gabbianelli M, Morsilli O, Massa A, Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia. Blood 2008;111:421-9
   PubMed Web of Science ®Google Scholar
• Borg J, Papadopoulos P, Georgitsi M, Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010;42:801-5
   PubMed Web of Science ®Google Scholar
• Bianchi N, Feriotto G, Gambari R, Mischiati C. Synthetic oligonucleotides as inducers of erythroid differentiation. PCTEP0102804; 2001
   Google Scholar
• Graslund T, Li X, Magnenat L, Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. J Biol Chem 2005;280:3707-14
   PubMed Web of Science ®Google Scholar
• Wilber A, Tschulena U, Hargrove PW, A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood 2010;115:3033-41
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2010;5:522-31
   Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610
   PubMed Web of Science ®Google Scholar
• Sontheimer EJ, Carthew RW. Silence from within: endogenous siRNAs and miRNAs. Cell 2005;122:9-12
   PubMed Web of Science ®Google Scholar
• Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005;132:4653-62
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Scepanovic D, MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA 2001;108:1519-24
   Web of Science ®Google Scholar
• Voon HP, Vadolas J. Controlling alpha-globin: a review of alpha-globin expression and its impact on beta-thalassemia. Haematologica 2008;93:1868-76
   PubMed Web of Science ®Google Scholar
• Voon HP, Wardan H, Vadolas J. siRNA-mediated reduction of alpha-globin results in phenotypic improvements in beta-thalassemic cells. Haematologica 2008;93:1238-42
   PubMed Web of Science ®Google Scholar
• Xie SY, Ren ZR, Zhang JZ, Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet 2007;16:2616-25
   PubMed Web of Science ®Google Scholar
• Voon HP, Wardan H, Vadolas J. Co-inheritance of alpha- and beta-thalassaemia in mice ameliorates thalassaemic phenotype. Blood Cells Mol Dis 2007;39:184-8
   PubMed Web of Science ®Google Scholar
• Fu YF, Du TT, Dong M, Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood 2009;113:1340-9
   PubMed Web of Science ®Google Scholar
• Wang B, Fang Y, Guo X, Transgenic human alpha-hemoglobin stabilizing protein could partially relieve betaIVS-2-654-thalassemia syndrome in model mice. Hum Gene Ther 2010;21:149-56
   PubMed Web of Science ®Google Scholar
• Free Patents Data Bank. Nottingham, MD, USA: FreePatentsOnline.com 2004 – 2012. Available from: http://www.freepatentsonline.com [Last accessed 14 February 2012]
   Google Scholar
• Espacenet. Munich, Germany: European Patent Office. 2012. Available from: http://worldwide.espacenet.com/ [Last accessed 14 February 2012]
   Google Scholar
• Clinical Trials Database. Bethesda, MD, USA: U.S. National Library of Medicine, 1993 – 2012. Available from: http://clinicaltrials.gov/ [Last accessed 14 February 2012]
   Google Scholar
• Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 2010;24:1005-20
   PubMed Web of Science ®Google Scholar
• Salvatori F, Breveglieri G, Zuccato C, Production of beta-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous beta039 thalassemia patients. Am J Hematol 2009;84:720-8
   PubMed Web of Science ®Google Scholar
• Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. London, UK: European medicines Agency, May 20, 2010. Available from: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500093309 [Last accessed 14 February 2012]
   Google Scholar
• Gambari R and Finotti A. Bioethics and freedom of scientific research in gene therapy and stem cell biology. In: Bin R, Lorenzon S, Lucchi N, editors. Biotech Innovations and Fundamental Rights. Springer; Heildelberg: 2012. p. 115-30
   Google Scholar
• Wilber A, Hargrove PW, Kim YS, Therapeutic levels of fetal hemoglobin in erythroid progeny of beta-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 2011;117:2817-26
   PubMed Web of Science ®Google Scholar
• Katada H, Komiyama M. Artificial restriction DNA cutters to promote homologous recombination in human cells. Curr Gene Ther 2011;11:38-45
   Google Scholar